Results 161 to 170 of about 3,601 (193)
Some of the next articles are maybe not open access.
American Journal of Clinical Dermatology, 2001
Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase which is thought to slow hair growth by inhibiting this enzyme in hair follicles. Percutaneous absorption of eflornithine in women with unwanted facial hair (hirsutism) was < 1% when the 15% cream was applied twice daily to a shaved 50 cm2 area of skin under the ...
J A, Balfour, K, McClellan
openaire +3 more sources
Eflornithine is a specific, irreversible inhibitor of the enzyme ornithine decarboxylase which is thought to slow hair growth by inhibiting this enzyme in hair follicles. Percutaneous absorption of eflornithine in women with unwanted facial hair (hirsutism) was < 1% when the 15% cream was applied twice daily to a shaved 50 cm2 area of skin under the ...
J A, Balfour, K, McClellan
openaire +3 more sources
Pharmaceutisch Weekblad, 1989
Eflornithine (alpha-difluoromethylornithine; DFMO) is a recently developed drug against African trypanosomiasis (sleeping sickness). After a short description of trypanosomiasis and the current treatment, the mechanism of action of eflornithine is discussed, some clinical data is given and attention is paid to recently discovered analogues of ...
I, Van Bogaert, A, Haemers
openaire +2 more sources
Eflornithine (alpha-difluoromethylornithine; DFMO) is a recently developed drug against African trypanosomiasis (sleeping sickness). After a short description of trypanosomiasis and the current treatment, the mechanism of action of eflornithine is discussed, some clinical data is given and attention is paid to recently discovered analogues of ...
I, Van Bogaert, A, Haemers
openaire +2 more sources
Treatment of Recurrent Gliomas With Eflornithine
JNCI Journal of the National Cancer Institute, 1992Oral eflornithine in combination with intravenous mitoguazone (methylbisguanylhydrazone) has shown activity against recurrent anaplastic gliomas. Eflornithine alone, however, has not been evaluated against recurrent gliomas.This study compared the antitumor activity of oral eflornithine with that of oral eflornithine combined with intravenous ...
V A, Levin +5 more
openaire +2 more sources
Eflornithine for the treatment of human African trypanosomiasis
Parasitology Research, 2003Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases. The most commonly used dosage regimen for the treatment of T. b.
Christian, Burri, Reto, Brun
openaire +2 more sources
Late-Stage African Trypanosomiasis and Eflornithine
Annals of Internal Medicine, 1986Excerpt To the editor: Human trypanosomiasis is a major public health problem in many African countries. At present, there is alarm at the recrudescence of this disease in its historical habitats.
CESARE DI BARI +4 more
openaire +1 more source
Does ▼eflornithine help women face hirsutism?
Drug and Therapeutics Bulletin, 2007Many women develop male-pattern facial hair (facial hirsutism), which can be distressing and difficult to treat. ▼Eflornithine (Vaniqa – Shire) is a topical cream available only on prescription for treating women with facial hirsutism. Promotional material claims that the treatment “slows facial hair growth – grows her confidence”.
openaire +2 more sources
Vaniqa--eflornithine 13.9% cream.
Skin therapy letter, 2001Eflornithine HCl 13.9% cream is the first topical prescription treatment to be approved by the US FDA for the reduction of unwanted facial hair in women. It irreversibly inhibits ornithine decarboxylase (ODC), an enzyme that catalyzes the rate-limiting step for follicular polyamine synthesis, which is necessary for hair growth.
J, Shapiro, H, Lui
openaire +1 more source
Eflornithine (Iwilfin) for High-Risk Neuroblastoma
The Medical Letter on Drugs and TherapeuticsEflornithine (Iwilfin – US WorldMeds), an oral ornithine decarboxylase inhibitor, has been approved by the FDA to reduce the risk of relapse in children and with high-risk neuroblastoma who had at least a partial response to prior multiagent, multimodality therapy, including anti-GD2 immunotherapy.
openaire +2 more sources